LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma — Bruno Sangro (2020) | RDL Network
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Thomas Yau, Joong‐Won Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Éric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou‐Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
Thomas Yau, J.W. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang–Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, G. Chen, Jaclyn Neely, Jeffrey Anderson, Bruno Sangro
Yubin Kang, Winnie Yeo, Akhil Chopra, Samira Soleymani, J. Yao, Jaclyn Neely, Marina Tschaika, Theodore H. Welling, Bruno Sangro, Anthony B. El-Khoueiry, Jörg Trojan, Tim Meyer, Thomas Yau, Ignacio Melero, Masatoshi Kudo, Chih‐Hung Hsu, T.-Y. Kim, Su Pin Choo
Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean–Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset,
Discussion(0)
No comments yet. Be the first to comment.